5-氯-N1-甲基苯-1,2-二胺 | 84859-27-8

• 物质功能分类: 分析化学 - 标准品 - 药典标准品和杂质标准品
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 5-氯-N1-甲基苯-1,2-二胺
• 英文名称: 5-chloro-N¹-methylbenzene-1,2-diamine
• 英文别名: 5-Chloro-N1-methylbenzene-1,2-diamine；4-chloro-2-N-methylbenzene-1,2-diamine
• CAS: 84859-27-8
• 化学式: C₇H₉ClN₂
• mdl: MFCD17676550
• 分子量: 156.615
• InChiKey: BTKCZOYKZRSPOQ-UHFFFAOYSA-N

物化性质

• 沸点：
  296.5±25.0 °C(Predicted)
• 密度：
  1.272±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  38
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2921590090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  5-氯-N1-甲基苯-1,2-二胺 在 N-羟基-7-氮杂苯并三氮唑 、 溶剂黄146 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 17.0h， 生成 benzyl 4-[(2S)-2-{[(tert-butoxy)carbonyl]amino}-2-(6-chloro-1-methyl-1H-1,3-benzodiazol-2-yl)ethyl]piperidine-1-carboxylate
  参考文献：
  名称：

  Nonacidic Chemotype Possessing N-Acylated Piperidine Moiety as Potent Farnesoid X Receptor (FXR) Antagonists

  摘要：

  Famesoid X receptor (FXR) plays a major role in the control of cholesterol metabolism. Antagonizing transcriptional activity of FXR is an effective means to treat the relevant metabolic syndrome. Some of antagonists so far have the charged functions; however, they may negatively affect the pharmacokinetics. We describe herein a structure activity relationship (SAR) exploration of nonacidic FXR antagonist 6 focusing on two regions in the structure and biological evaluation of nonacidic 10 with the characteristic N-acylated piperidine group obtained from SAR studies. As the robust affinity to FXR is feasible with our nonacidic analogue, 10 is among the most promising candidates for in vivo testing.

  DOI：

  10.1021/acsmedchemlett.7b00363
• 作为产物：
  描述：

  2,4-二氯硝基苯 在 氢气 、 铜 作用下， 以 乙醇 、 水 为溶剂， 20.0~100.0 ℃ 、101.33 kPa 条件下， 反应 11.0h， 生成 5-氯-N1-甲基苯-1,2-二胺
  参考文献：
  名称：

  Discovery of 2-iminobenzimidazoles as potent hepatitis C virus inhibitors with a novel mechanism of action

  摘要：

  In this report we describe 2-iminobenzimidazole (IBI) analogs, identified during the course of a phenotypic high-throughput screening campaign, as novel hepatitis C virus (HCV) inhibitors. A series of IBI derivatives was synthesized and evaluated for their inhibitory activity against infectious HCV. Among the IBIs derivatives studied in this work, we identified promising compounds with high antiviral efficacy, high selectivity index and good microsomal stability. Noteworthy, the IBI series exhibited inhibitory activity on early and late steps of the viral cycle, but not in the HCV replicon system demonstrating a mechanism of action distinct from clinical-stage and approved anti-HCV drugs. Overall, our results suggest that IBIs are predestinated for further exploration as lead compounds for novel HCV interventions. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.03.030

文献信息

• Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators
  申请人：Egle Ian

  公开号：US20090192169A1

  公开（公告）日：2009-07-30

  Compounds of Formula I: wherein A, B, D, L, R 1 , R 2 , R 3 , R 4 , m, and n are as defined for Formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.

  式I的化合物： 其中A、B、D、L、R1、R2、R3、R4、m和n的定义如描述中所定义。本发明还涉及制备这些化合物的方法，以及用于制备的新中间体，含有这些化合物的药物组合物，以及这些化合物在治疗中的应用。
• [EN] ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS<br/>[FR] DÉRIVÉS D'ARYL-PYRIDINE EN TANT QU'INHIBITEURS D'ALDOSTÉRONE SYNTHASE
  申请人：NOVARTIS AG

  公开号：WO2011061168A1

  公开（公告）日：2011-05-26

  The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5 and n are defined herein. The invention also relates to a method for manufacturing compounds of the invention, and their therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了式（I）的化合物或其药学上可接受的盐，其中R1、R2、R3、R4、R5和n在此处定义。该发明还涉及一种制造该发明化合物的方法，以及它们的治疗用途。本发明还提供了一种药理活性剂的组合和制药组合物。
• C2-Selective Branched Alkylation of Benzimidazoles by Rhodium(I)-Catalyzed C–H Activation
  作者：Gaël Tran、Danielle Confair、Kevin D. Hesp、Vincent Mascitti、Jonathan A. Ellman

  DOI：10.1021/acs.joc.7b01723

  日期：2017.9.1

  Herein, we report a Rh(I)/bisphosphine/K3PO4 catalytic system allowing for the first time the selective branched C–H alkylation of benzimidazoles with Michael acceptors. Branched alkylation with N,N-dimethyl acrylamide was successfully applied to the alkylation of a broad range of benzimidazoles incorporating a variety of N-substituents and with both electron-rich and -poor functionality displayed

  在本文中，我们报道了Rh（I）/双膦/ K 3 PO 4催化体系，首次使苯并咪唑与Michael受体进行了选择性支链C–H烷基化。用N，N-二甲基丙烯酰胺进行的支化烷基化已成功地用于各种苯并咪唑的烷基化反应，这些苯并咪唑掺入了各种N-取代基，并且在芳烃的不同部位均显示出富电子和贫电子的功能。此外，通过用甲基丙烯酸乙酯进行烷基化来引入季碳。该方法还显示出可用于氮杂苯并咪唑的C 2-选择性支链烷基化。
• Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
  申请人：Borchardt Allen

  公开号：US20050176701A1

  公开（公告）日：2005-08-11

  The invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R 1 and R 2 , are as defined herein. The invention also relates to methods of treating Hepatitis C virus in mammals by administering the compounds of formula 1, and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.

  这项发明涉及公式1的化合物，以及其药学上可接受的盐、溶剂化合物、前药和代谢物，其中W、Z、R1和R2如本文所定义。该发明还涉及通过给哺乳动物施用公式1的化合物来治疗丙型肝炎病毒的方法，以及用于治疗这类疾病的含有公式1化合物的药物组合物。该发明还涉及制备公式1化合物的方法。
• [EN] ARYL HYDROCARBON RECEPTOR ACTIVATORS<br/>[FR] ACTIVATEURS DU RÉCEPTEUR D'HYDROCARBURE ARYLE
  申请人：UNIV OREGON STATE

  公开号：WO2021022061A1

  公开（公告）日：2021-02-04

  Small molecule AhR ligands are disclosed. The ligands can induce the differentiation of Tr1 cells to suppress pathogenic immune responses without inducing nonspecific immune suppression. Methods of treatment of autoimmune diseases using the AhR ligands are also disclosed.

  披露了小分子AhR配体。这些配体可以诱导Tr1细胞分化，抑制病原免疫反应，而不引起非特异性免疫抑制。还披露了使用AhR配体治疗自身免疫疾病的方法。